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cultured in the β-thalassemia patient sera and β-thalassemic mice 4 
 5 
Supranee Upanan1, Andrew T. McKie2, Gladys O. Latunde-Dada2, Chairat Uthaipibull3, Suthat 6 
Fucharoen4, Somdet Srichairatanakool1* 7 
 8 
1Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200 Thailand 9 
2Division of Diabetes and Nutritional Sciences, King’s College London, London, SE1 9NH, United 10 
Kingdom 11 
3National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology 12 
Development Agency (NSTDA), Science Park, Pathumthani 12120 Thailand 13 
4 Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University Salaya Campus, 14 
Nakornpathom 73170 Thailand 15 
 16 
 17 
KEY WORDS: Atoh8, HAMP, Thalassemia, Iron overload, erythropoiesis 18 
 19 
 20 
 21 
2 
 
ABSTRACT 1 
Objective: This study aimed to demonstrate the down-regulation of Atoh8 relating to hepcidin 2 
suppression in β-thalassemia. Methods: HuH7 cells were cultured in DMEM medium 3 
supplemented with 20% β-thalassemia patient sera (HbE/β-thalassemia and β-thalassemia major) 4 
or normal serum as a control. To investigate the effect of Atoh8 on HAMP transcription in β-5 
thalassemia, HEK293 cells were transfected with ATOH8-FLAG expression plasmid and cultured 6 
in DMEM medium supplemented with 20% β-thalassemia patient sera. Atoh8 and HAMP mRNA 7 
expression were analyzed by qPCR, and HAMP promoter activity was detected by the luciferase 8 
reporter assay. In addition, hepatic Atoh8 and Hamp1 mRNA expression in β-thalassemic mice 9 
were also determined. Results:  In the cultured HuH7 cells, HAMP mRNA levels and HAMP 10 
promoter activity in all β-thalassemia serum groups were significantly lower than the normal serum 11 
group. Interestingly, our study found that Atoh8 expression was down-regulated in the same 12 
direction as HAMP expression being suppressed despite iron overload. The Atoh8 transfection 13 
could enhance HAMP expression in endogenous HAMP mRNA levels as well as HAMP promoter 14 
activity in HEK293 cells cultured in the β-thalassemia patient sera. In accordance with this, hepatic 15 
Atoh8 and Hamp1 mRNA expression in β-thalassemic mice were also down-regulated. 16 
Conclusion: It’s likely that the increased erythropoietic activity in β-thalassemia would suppress 17 
Atoh8 expression, subsequently down-regulating hepcidin expression. Therefore, Atoh8 would be 18 
a novel regulator of HAMP transcription in the β-thalassemia. 19 
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1. Introduction  1 
Hepcidin, an iron regulatory hormone, is a 25-amino acid peptide produced by hepatocytes 2 
in the liver (1-6). It plays a critical role in the balance of systemic iron homeostasis by inducing 3 
the internalization and degradation of the iron- exporter ferroportin on enterocytes, hepatocytes 4 
and macrophages (7-11). Thus the increase of hepcidin inhibits duodenal iron absorption and iron 5 
release form hepatocytes and macrophages. This can limit iron overload; however, urinary and 6 
serum hepcidin levels in β-thalassemia are reduced (12-15) leading to increased iron absorption 7 
which exacerbates iron overload condition.  8 
Hepatic hepcidin (HAMP) mRNA expression is regulated in by three major stimuli including 9 
iron levels, inflammation and erythropoietic activity via different signal transduction pathways. 10 
The regulation of HAMP transcription responds to changes of tissue iron though the bone 11 
morphogenic protein (BMP) signaling pathway and a change of hepatic BMP6 levels (16, 17). The 12 
HAMP transcription is activated by the inflammation via STAT-3 signaling pathway (18). The 13 
signal transduction pathway to regulate HAMP transcription under the erythropoietic activity 14 
remains unclear. Two molecules produced by erythroid precursors, the growth differentiation 15 
factor 15 (GDF15) and the twisted gastrulation factor 1 (TWSG1), and the bone morphogenetic 16 
protein binding endothelial cell precursor-derived regulator (BMPER) produced by endothelial 17 
cells have been reported as the negative regulator of HAMP transcription by BMP signaling 18 
pathway (19-22). In addition, a recent study suggested that erythroferrone (ERFE), produced by 19 
erythroid precursors, acts as a new erythroid-derived hormone and inhibits hepcidin expression 20 
during stress erythropoiesis (23). In β-thalassemia studies, Tanno et al demonstrated that GDF15 21 
levels were elevated in β-thalassemia patient serum with low hepcidin and that GDF15 suppressed 22 
hepcidin mRNA expression in human hepatocyte cultures (19). In contrast, Casanovas et al 23 
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reported that the hepcidin expression was suppressed in Gdf-15-/- mice subjected to phlebotomy 1 
and that bone marrow GDF15 were not increased in the β-thalassemic mice (24). Therefore, the 2 
relationship between GDF15 and hepcidin regulation remains controversial. TWSG1 interfered 3 
with BMP-mediated hepcidin expression in human hepatocyte cultures and was up-regulated in 4 
the β-thalassemic mice (20). ERFE mRNA expression was increased in the β-thalassemic mice, 5 
and hepcidin suppression in ERFE-deficient mice was failed after hemorrhage (23). However, 6 
human correlative studies of TWSG1 and ERFE have not been investigated yet.  7 
Recently, Patel et al (25) has identified Atoh8, atonal homolog 8 (Drosophila), as a novel 8 
positive regulator of HAMP transcription via two independent mechanisms: E-box dependent 9 
transcriptional activation; and the increase of cellular pSMAD1,5,8 levels in BMP signaling 10 
pathway. In addition, the down-regulation of Atoh8 was observed in mice with increased 11 
erythropoietic activity, which appears to override the activation of Atoh8 by the increased iron 12 
levels.  All of these explain how hepcidin suppression was carried on by increased erythropoietic 13 
activity in the conditions of liver iron loading and increased BMP6 levels without any change in 14 
pSMAD1,5,8 levels (26). Given that the increased erythropoiesis activity suppressed Atoh8 15 
expression similar to hepcidin expression we hypothesized that Atoh8 may be a novel candidate 16 
transcriptional regulator of HAMP in the β-thalassemia. 17 
 18 
2. Materials and Methods 19 
2.1. β-Thalassemia serum samples 20 
10-18 years old male (N=11) and female (N=12) HbE/β-thalassemia patients (HbE/T-Male 21 
and HbE/T-Female) and male (N=9) and female (N=6) β-thalassemia major patients (TM-Male 22 
and TM-Female) from Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand were the 23 
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volunteers for this research. The β-thalassemia patients are usually treated with iron chelator(s) 1 
(DFP, DFO or DFX) and regularly receive blood transfusion. The experimental protocol was 2 
conducted with the approval of the Research Ethics Committee, Faculty of Medicine, Chiang Mai 3 
University, Thailand (Research ID: 2151/ Study Code: BIO-2556-02151). Their bloods were 4 
collected monthly for 3 months before they receive the blood transfusion. The bloods were 5 
collected into 5-ml vacuum tubes, left to clot at room temperature for 30 minutes and centrifuged 6 
at 3,000g for 10 minutes. The sera were collected at stored at -20ºC until use. All sera in the same 7 
group were pooled together and blood iron parameters were determined. Serum Iron (SI) and Total 8 
Iron Binding Capacity (TIBC) were analyzed by Clinical Chemistry Laboratory, Maharaj Nakorn 9 
Chiang Mai Hospital, Chiang Mai, Thailand. Non-transferrin bound iron (NTBI) concentrations 10 
were measured by using NTA chelation/HPLC method (27). Serum ferritin levels were analyzed 11 
by Tumor Maker Laboratory, Faculty of Medicine, Chiang Mai University, Thailand. Serum 12 
hepcidin levels were estimated by using Hepcidin (Hepc) ELISA Kit (CEB979Hu, Uscn Life 13 
Science Inc., Hubei, China). 14 
2.2. Cell culture and cell transfection 15 
2.2.1. Cell culture 16 
Human hepatoma cell lines (HuH7) or human embryonic kidney 293 cell lines (HEK293) were 17 
cultured in DMEM medium supplemented with 10% (v/v) fetal bovine serum (FBS), 2 mM L-18 
glutamine and 1% penicillin-streptomycin and incubated at 37°C under a humidified 5% CO2 19 
atmospheric condition. 20 
The conditions for culturing cells in human sera were determined to imitate β-thalassemia 21 
patients as previously described (28). 24-hour (60% confluent) grown cells were starved in serum-22 
free DMEM medium supplemented with 1% penicillin-streptomycin for 24 hours as a starvation 23 
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step. Subsequently, the medium was removed and the cells were grown in DMEM medium 1 
supplemented with 20% human sera [Normal (Invitrogen, UK), male HbE/ β-thalassemia, female 2 
HbE/ β-thalassemia, male β-thalassemia major and female β-thalassemia major], 2 mM L-3 
glutamine and 1% penicillin-streptomycin for 24 hours. HAMP and Atoh8 mRNA expression were 4 
analyzed by qPCR.  5 
2.2.2. Cell transfection 6 
2.2.2.1. HAMP promoter transfection in HuH7 cells 7 
To confirm endogenous HAMP mRNA levels from qPCR result, the HAMP promoter assay 8 
was performed. Before the cells were grown in DMEM medium supplemented with human sera, 9 
HAMP reporter plasmid was co-transfected with a TK-renilla control reporter plasmid at a 1:4 ratio 10 
in serum-free DMEM medium supplemented with 1% penicillin-streptomycin into the HuH7 cells 11 
for 24 hours in the starvation step as mentioned above by using Fugene 6 (Promaga, UK) according 12 
to the manufacturer’s instructions (29). After the transfected cells were grown in DMEM medium 13 
supplemented with human sera, HAMP promoter activity was detected by luciferase reporter assay. 14 
2.2.2.2. Atoh8 and HAMP promoter transfection in HEK293 cells 15 
To study the effect of Atoh8 on HAMP transcription, HEK293 cells, known as the model for 16 
Atoh8 transfection as the previous study (25), were transfected with ATOH8-FLAG expression 17 
plasmid or empty plasmid (Origen vector) in serum-free DMEM medium supplemented with 1% 18 
penicillin-streptomycin for 6 hours in the starvation step as mentioned above by using Fugene 6. 19 
After the transfected cells were grown in DMEM medium supplemented with human sera, Atoh8 20 
mRNA and HAMP mRNA expression were determined by qPCR. 21 
For HAMP promoter assay, HAMP reporter plasmid was co-transfected with a TK-renilla 22 
control reporter plasmid (1:4 ratio) and ATOH8-FLAG expression plasmid in serum-free DMEM 23 
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medium supplemented with 1% penicillin-streptomycin into the HEK293 cells for 6 hours in the 1 
starvation step by using Fugene 6 (25). After the transfected cells were grown in DMEM medium 2 
supplemented with human sera, HAMP promoter activity was detected by the luciferase reporter 3 
assay. 4 
2.3. Animals 5 
7-8 months old male (N=5) and female (N=5) C57/BL6, wild type (WT, muβ+/+) and 6 
heterozygous β-globin knockout (BKO, muβth-3/+), were kindly supplied by Thalassemia Research 7 
Center, Institute of Molecular Bioscience, Mahidol University, Salaya Campus, Thailand (30, 31) 8 
and conducted under the Animal Ethical Committee of Medical Faculty, Chiang Mai University, 9 
Thailand (Reference Number 42/2556). The mice were sacrificed and their livers were collected 10 
to determine hepcidin1 (Hamp1) and Atoh8 mRNA expression by qPCR. 11 
2.4. RNA extraction and cDNA synthesis 12 
RNA was extracted from HuH7 cells or HEK293 cells by using TRIzol reagent (Invitrogen, 13 
UK). In mice, RNA was extracted from 100 mg of liver by using TRIzol and the genomic DNA 14 
was removed by using Illustra RNAspin Mini RNA Isolation Kit (GE Healthcare, 15 
Buckinghamshire, UK) according to the manufacturer’s protocol. 1 µg of RNA was reverse 16 
transcribed into complementary DNA (cDNA) using High Capacity cDNA Reverse Transcription 17 
Kit (Applied Biosystems, Foster City, USA). 18 
2.5. Quantitative real-time PCR (qPCR) 19 
2.5.1. In cell culture 20 
 The qPCR reactions of cDNA were performed using TaqMan Gene Expression Assay 21 
(Applied Biosystems) on the ABI PRISM 7900 HT PCR machine (Applied Biosystems, Paisley, 22 
UK) or ABI 7500 fast real-time PCR machine (Applied Biosystems, Paisley, UK) according to the 23 
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manufacturer’s protocol. mRNA expression of HAMP (Hs00221783_m1) or Atoh8 1 
(Hs01031629_m1) was normalized to housekeeping gene RLP19 (Hs01577060_gH) and 2 
expressed as a fold change by using ∆∆CT method (32). 3 
2.5.2. In mice 4 
The qPCR reactions of cDNA were performed using EXPRESS SYBR® GreenER™ qPCR 5 
Supermix Universal Kits (Invitrogen, Carlsbad, CA, USA) on the ABI 7500 real-time PCR 6 
machine (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer’s protocol. The 7 
primer sequences used in qPCR are presented as follows; mHamp1 forward: 8 
CCTGAGCAGCACCACCTATC, mHamp1 reverse: TGCAACAGATACCACACTGGG, 9 
mAtoh8 forward: TCAGCTTCTCCGAGTGTGTG, mAtoh8 reverse: 10 
TAGCCTGTGGCAGGTCACT (25), mActb forward: GGTCCACACCCGCCAC, mActb reverse: 11 
GTCCTTCTGACCCATTCCCA. mRNA expression of Hamp1 or Atoh8 was normalized to 12 
housekeeping gene  β-actin (Actb) and expressed as a fold change by using ∆∆CT method (32). 13 
2.6. Luciferase reporter assays 14 
The luminescence from HuH7 cells or HEK293 cells was detected by using Dual-Luciferase 15 
Reporter Assay according to the manufacturer’s instructions (Promaga, UK) and measured by a 16 
luminometer (Promaga, UK). Relative luciferase activity was calculated from the ratio of the signal 17 
of firefly luciferase to TK-renilla luciferase and expressed as the fold change to the control group. 18 
2.7. Statistical Analysis 19 
The data are presented as means±SD. Data analysis was undertaken by using SPSS program, 20 
and statistical significance was determined by using one-way analysis of variance (ANOVA). The 21 
p value <0.05 was considered significant. 22 
 23 
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3. Results 1 
3.1. Blood iron parameters 2 
The blood iron parameters of the pooled human sera: normal, male HbE/ β-thalassemia, 3 
female HbE/ β-thalassemia, male β-thalassemia major and female β-thalassemia major were 4 
analyzed as shown in the Table 1. Serum iron, transferrin saturation, plasma NTBI and plasma 5 
ferritin levels in all β-thalassemia patient sera were higher than those in normal serum although 6 
plasma hepcidin levels were not different, suggesting that the thalassemia patient sera have iron 7 
overload condition. 8 
3.2. Effect of β-thalassemia patient sera on HAMP and Atoh8 expression in HuH7 cells 9 
After 24-hour (60% confluent) grown HuH7 cells were starved in serum-free DMEM 10 
medium for 24 hours, HuH7 cells were cultured in DMEM medium supplemented with 20% 11 
human sera: normal, male HbE/ β-thalassemia, female HbE/ β-thalassemia, male β-thalassemia 12 
major and female β-thalassemia major for 24 hours. Subsequently, HAMP and Atoh8 mRNA 13 
expression were detected by qPCR. HAMP (Figure 1A) and Atoh8 (Figure 1B) mRNA levels and 14 
HAMP promoter activity (Figure 2) in all β-thalassemia serum groups were significantly lower 15 
than those in the normal serum group, and there was no difference between genders. Interestingly, 16 
our study demonstrated that β-thalassemia patients have not only the decreased HAMP expression 17 
but also the reduced Atoh8 expression. 18 
3.3. Hepatic Hamp1 and Atoh8 mRNA expression in β-thalassemic mice 19 
Hepatic Hamp1 (Figure 3A) and Atoh8 (Figure 3B) mRNA levels in BKO mice were lower 20 
than those in WT mice but significantly in female. However, the Hamp1 and Atoh8 mRNA 21 
expression were not different between genders.  22 
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3.4. Effect of Atoh8 transfection on HAMP expression in HEK293 cells grown in β-1 
thalassemia patient sera 2 
To determine whether Atoh8 regulates HAMP transcription in β-thalassemia, HEK293 cells 3 
were transfected with increasing amounts of the ATOH8-FLAG expression plasmid and grown in 4 
the β-thalassemia patient sera. The HEK293 cells were transfected with 0.5, 1, 2 and 4 ug ATOH8-5 
FLAG expression plasmid and grown in DMEM medium containing 20% female HbE/ β-6 
thalassemia serum for 24 hours. The Atoh8 transfection could significantly induce Atoh8 mRNA 7 
expression (Figure 4A) and up-regulate HAMP mRNA expression (Figure 4B) in the dose-8 
dependent manner at 2 and 4 µg ATOH8-FLAG expression plasmid. In accordance with 9 
endogenous HAMP mRNA levels, HAMP promoter activity was more sensitive and significantly 10 
increased in the dose-dependent manner with 0.5, 1 and 2 µg ATOH8-FLAG expression plasmid 11 
(Figure 5). Furthermore, the Atoh8 transfection could significantly and markedly enhance HAMP 12 
expression in both endogenous HAMP mRNA and HAMP promoter activity not only in the female 13 
HbE/ β-thalassemia serum group but also in normal, male HbE/ β-thalassemia, male β-thalassemia 14 
major and female β-thalassemia major serum group (Figure 6 and 7).  The empty plasmid (Origen 15 
vector) did not effect on Atoh8 (Figure 6A) and HAMP (Figure 6B) mRNA levels as well as 16 
HAMP promoter activity (Figure 7A) when compared to the untransfected ATOH8-FLAG group. 17 
Thus the Atoh8 transfection could up-regulate the expression of Atoh8 probably subsequently 18 
activating HAMP expression. 19 
 20 
4. Discussion 21 
The down-regulation of hepcidin expression in β-thalassemic mice (33-38) and the low 22 
hepcidin levels in β-thalassemia patients (12-15, 39) have been previously reported. Although our 23 
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study showed the indifference of hepcidin levels between β-thalassemia patient serum and normal 1 
serum as the previous studies (15, 40, 41), HepG2 grown in the medium containg the thalassemia 2 
sera revealed the down-regulation of hepcidin expression (28, 40). Interestingly, this study 3 
demonstrated that not only hepcidin but also Atoh8 was down-regulated in β-thalassemia. The 4 
decrease of Atoh8 mRNA levels also related to the reduction of HAMP expression, endogenous 5 
HAMP mRNA and HAMP promoter activity, in the HuH7 cells cultured in DMEM medium 6 
supplemented with 20% β-thalassemia patient sera for 24 hours. In this condition, erythropoietic 7 
regulatory proteins still effect on HAMP expression as same as in the patients. According to the 8 
suppression of hepatic Atoh8 and hepcidin expression in the mice under the conditions with an 9 
increased erythropoiesis activity (e.g. hemolytic anemia, hypoxia, erythropoietin treatment, and 10 
hypotransferrinaemia) (21, 25, 42-46), this study also showed the lower hepatic Atho8 mRNA 11 
levels related to the decreased hepatic Hamp1 mRNA levels in β-thalassemic mice. Courselaud 12 
and colleagues demonstrated that hepcidin expression varied between genders of mice (47), but 13 
not in some study (41) as well as our data Atho8 and hepcidin expression in the β-thalassemia 14 
patient serum groups and in the β-thalassemic mice were not different between genders.  In 15 
addition to erythropoietic activity, Atoh8 expression responded to a change of iron levels. Hepatic 16 
Atoh8 and Hamp1 mRNA levels were increased in mice fed with an iron supplemented-diet and 17 
in mice treated with holo-transferrin, whereas those were decreased in mice fed with an iron 18 
deficient-diet (25, 48). Conversely, Atoh8 and HAMP mRNA expression were suppressed in HuH7 19 
cells cultured in the medium containing the β-thalassemia patient sera even though their serum 20 
iron and transferrin saturation levels are very high. Similarly, in hypotransferrinaemic (HPX) mice 21 
with high degree of chronic anemia and liver iron overload, hepatic Atoh8 and Hamp1 expression 22 
were also down-regulated (21, 25). Atoh8 mRNA expression was also inhibited in Hamp1-/- mice 23 
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after PHZ treatment although their serum iron was still high (25, 44). As previously shown, it is 1 
likely that the up-regulation of Atoh8 by iron was overridden by the increased erythropoiesis 2 
activity similar to the regulation of hepcidin. Therefore, in β-thalassemia Atoh8 expression was 3 
suppressed by the increased erythropoiesis activity in a similar manner and direction to hepcidin 4 
expression. 5 
Furthermore, Atoh8 expression was also suppressed in Hamp1-/- mice after PHZ treatment 6 
increasing erythropoiesis activity, suggesting that Atoh8 is an upstream regulator of Hamp1 (25). 7 
In HEK293 cells, Atho8 could stimulate HAMP transcription in two ways, directly via E-boxes 8 
and indirectly through increased pSMAD1,5,8 levels (25). In this study, Atoh8 transfection in 9 
HEK293 cultured in the medium containing the β-thalassemia patient sera could induce the HAMP 10 
expression in both endogenous mRNA and promoter activity. It suggested that the down-regulation 11 
of Atoh8 expression in β-thalassemia resulted from the increased erythropoietic activity and 12 
subsequently leaded to the decrease of HAMP expression. Therefore, in β-thalassemia Atoh8 may 13 
be a novel transcriptional regulator of HAMP, which is responsive to the erythropoietic activity. 14 
This is a new research for therapies and management in β-thalassemia patients.   15 
 16 
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Table 1 Blood iron parameters of human sera 1 
Blood chemistry Normal 
HbE/T-
Male 
HbE/T-
Female 
TM-
Male 
TM-
Female 
SI (µg/dl) 52 140 135 161 155 
TIBC (µg/dl) 339 148 135 161 155 
Transferrin 
saturation (%) 15.34 94.59 100 100 100 
NTBI (µM) -0.39 7.31 7.77 5.46 4.07 
Ferritin (ng/ml) 26.31 1307 1812 2000 1405 
Hepcidin (ng/ml) 34.69 42.78 38.08 32.90 47.76 
2 
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Figure legends 1 
Figure 1 Effect of β-thalassemia patient sera on HAMP and Atoh8 mRNA expression in HuH7 2 
cells grown in DMEM medium supplemented with 20% human sera for 24 hours. Relative 3 
HAMP (A) and Atoh8 (B) mRNA expression from qPCR analysis were acquired by normalizing 4 
HAMP mRNA or Atoh8 mRNA to RPL19 mRNA. The samples were determined in quadruplicate 5 
in two independent experiments. Values are expressed as mean+SD derived from a single 6 
experiment with four biological replicates for the fold change as compared to the normal serum 7 
group. The experiment shown is representative of two similar experiments. *p<0.05 when 8 
compared with the normal serum group. 9 
Figure 2 Effect of β-thalassemia patient sera on HAMP promoter activity in HuH7 cells co-10 
transfected with HAMP reporter plasmid and TK-renilla and grown i n  D ME M medium 11 
supplemented with 20% human sera for 24 hours . Promoter activity was expressed as the 12 
relative luciferase activity to the normal serum group. The samples were determined in triplicate. 13 
Values are expressed as mean+SD for the fold change as compared to the normal serum group. 14 
*p<0.05 when compared with the normal serum group. 15 
Figure 3 Hepatic Hamp1 and Atoh8 mRNA expression of male (N=5) and female (N=5) mice. 16 
Relative Hamp1 (A) and Atoh8 (B) mRNA expression in WT and BKO mice from qPCR analysis 17 
were acquired by normalizing Hamp1 mRNA or Atoh8 mRNA to Actb mRNA. Vales are expressed 18 
as mean+SD for the fold change as compared to the WT-male group. 19 
Figure 4 Atoh8 and HAMP mRNA expression in HEK293 cells transfected with (1, 2 and 4 20 
µg) ATOH8-FLAG expression plasmid and grown in DMEM medium supplemented with 21 
20% female HbE/  β-thalassemia serum for 24 hours . Relative Atoh8 (A) and HAMP (B) 22 
mRNA expression from qPCR analysis were acquired by normalizing Atoh8 mRNA or HAMP 23 
19 
 
mRNA to RPL19 mRNA. The samples were determined in triplicate. Values are expressed as 1 
mean+SD for the fold change as compared to the untransfected ATOH8-FLAG group. *p<0.05 2 
when compared with the untransfected ATOH8-FLAG group. 3 
Figure 5 HAMP promoter activity in HEK293 cells co-transfected with HAMP reporter 4 
plasmid, TK-renilla and (0.5, 1 and 2 µg) ATOH8-FLAG expression plasmid and grown in 5 
DMEM medium supplemented with 20% female HbE/ β-thalassemia serum for 24 hours. 6 
Promoter activity was expressed as the relative luciferase activity to the untransfected ATOH8-7 
FLAG group. The samples were determined in triplicate. Values are expressed as mean+SD for 8 
the fold change as compared to the untransfected ATOH8-FLAG group. *p<0.05 when compared 9 
with the untransfected ATOH8-FLAG group. 10 
Figure 6 Atoh8 and HAMP mRNA expression in HEK293 cells transfected with (2 µg) 11 
ATOH8-FLAG expression plasmid or empty plasmid (Origen vector) and grown in DMEM 12 
medium supplemented with 20% human sera for 24 hours . Relative Atoh8 (A) and HAMP 13 
(B) mRNA expression from qPCR analysis were acquired by normalizing Atoh8 mRNA or HAMP 14 
mRNA to RPL19 mRNA. The samples were determined in triplicate. Values are expressed as 15 
mean+SD for the fold change as compared to the untransfected ATOH8-FLAG group. 16 
Figure 7 HAMP promoter activity in HEK293 cells co-transfected with HAMP reporter 17 
plasmid, TK-renilla and (0.5 and 1 µg) ATOH8-FLAG expression plasmid (or Origen 18 
vector) and grown in DMEM medium supplemented with 20% human sera (A: Female 19 
HbE/β-thalassemia, B: Normal, C: Male HbE/β-thalassemia, D: Male β-thalassemia major, 20 
D: Female β-thalassemia major) for 24 hours. Promoter activity was expressed as the relative 21 
luciferase activity to the untransfected ATOH8-FLAG group. The samples were determined in 22 
20 
 
triplicate. Values are expressed as mean+SD for the fold change as compared to the untransfected 1 
ATOH8-FLAG group. *p<0.05 when compared with the untransfected ATOH8-FLAG group. 2 
 3 
21 
 
 1 
2 
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Figure 1 Effect of β-thalassemia patient sera on HAMP and Atoh8 mRNA expression in HuH7 4 
cells grown in DMEM medium supplemented with 20% human sera for 24 hours. Relative 5 
HAMP (A) and Atoh8 (B) mRNA expression from qPCR analysis were acquired by normalizing 6 
HAMP mRNA or Atoh8 mRNA to RPL19 mRNA. The samples were determined in quadruplicate 7 
in two independent experiments. Values are expressed as mean+SD derived from a single 8 
experiment with four biological replicates for the fold change as compared to the normal serum 9 
group. The experiment shown is representative of two similar experiments. *p<0.05 when 10 
compared with the normal serum group. 11 
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Figure 2 Effect of β-thalassemia patient sera on HAMP promoter activity in HuH7 cells co-2 
transfected with HAMP reporter plasmid and TK-renilla and grown i n  D ME M medium 3 
supplemented with 20% human sera for 24 hours . Promoter activity was expressed as the 4 
relative luciferase activity to the normal serum group. The samples were determined in triplicate. 5 
Values are expressed as mean+SD for the fold change as compared to the normal serum group. 6 
*p<0.05 when compared with the normal serum group. 7 
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Figure 3 Hepatic Hamp1 and Atoh8 mRNA expression of male (N=5) and female (N=5) mice. 3 
Relative Hamp1 (A) and Atoh8 (B) mRNA expression in WT and BKO mice from qPCR analysis 4 
were acquired by normalizing Hamp1 mRNA or Atoh8 mRNA to Actb mRNA. Vales are expressed 5 
as mean+SD for the fold change as compared to the WT-male group. 6 
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Figure 4 Atoh8 and HAMP mRNA expression in HEK293 cells transfected with (1, 2 and 4 3 
µg) ATOH8-FLAG expression plasmid and grown in DMEM medium supplemented with 4 
20% female HbE/  β-thalassemia serum for 24 hours . Relative Atoh8 (A) and HAMP (B) 5 
mRNA expression from qPCR analysis were acquired by normalizing Atoh8 mRNA or HAMP 6 
mRNA to RPL19 mRNA. The samples were determined in triplicate. Values are expressed as 7 
mean+SD for the fold change as compared to the untransfected ATOH8-FLAG group. *p<0.05 8 
when compared with the untransfected ATOH8-FLAG group. 9 
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 1 
Figure 5 HAMP promoter activity in HEK293 cells co-transfected with HAMP reporter 2 
plasmid, TK-renilla and (0.5, 1 and 2 µg) ATOH8-FLAG expression plasmid and grown in 3 
DMEM medium supplemented with 20% female HbE/ β-thalassemia serum for 24 hours. 4 
Promoter activity was expressed as the relative luciferase activity to the untransfected ATOH8-5 
FLAG group. The samples were determined in triplicate. Values are expressed as mean+SD for 6 
the fold change as compared to the untransfected ATOH8-FLAG group. *p<0.05 when compared 7 
with the untransfected ATOH8-FLAG group. 8 
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 2 
Figure 6 Atoh8 and HAMP mRNA expression in HEK293 cells transfected with (2 µg) 3 
ATOH8-FLAG expression plasmid or empty plasmid (Origen vector) and grown in DMEM 4 
medium supplemented with 20% human sera for 24 hours. Relative Atoh8 (A) and HAMP (B) 5 
mRNA expression from qPCR analysis were acquired by normalizing Atoh8 mRNA or HAMP 6 
mRNA to RPL19 mRNA. The samples were determined in triplicate. Values are expressed as 7 
mean+SD for the fold change as compared to the untransfected ATOH8-FLAG group. 8 
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Figure 7 HAMP promoter activity in HEK293 cells co-transfected with HAMP reporter 4 
plasmid, TK-renilla and (0.5 and 1 µg) ATOH8-FLAG expression plasmid (or Origen 5 
vector) and grown in DMEM medium supplemented with 20% human sera (A: Female 6 
HbE/β-thalassemia, B: Normal, C: Male HbE/β-thalassemia, D: Male β-thalassemia major, 7 
D: Female β-thalassemia major) for 24 hours. Promoter activity was expressed as the relative 8 
luciferase activity to the untransfected ATOH8-FLAG group. The samples were determined in 9 
triplicate. Values are expressed as mean+SD for the fold change as compared to the untransfected 10 
ATOH8-FLAG group. *p<0.05 when compared with the untransfected ATOH8-FLAG group. 11 
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